ライフサイエンスコーパス: beneficiary

1 nly enrolled in Medicare (nondually enrolled beneficiaries).

2 on Category risk score among fee-for-service beneficiaries).

3 operating prior to 2014, representing 78% of beneficiaries).

4 isional surgery, and mean eye care costs per beneficiary.

5 interquartile range (IQR): $554-$15,181] per beneficiary.

6 loric intake of the benefactor vis-a-vis the beneficiary.

7 .76%-3.79%) in 2017 among nondually enrolled beneficiaries.

8 cally underpredicts costs for frail Medicare beneficiaries.

9 table quality among Medicare fee-for-service beneficiaries.

10 21%-20.31%) in 2017 among nondually enrolled beneficiaries.

11 iovascular prescription drugs among Medicaid beneficiaries.

12 ditional Medicare but not Medicare Advantage beneficiaries.

13 ltured and egg-based vaccines among Medicare beneficiaries.

14 beneficiaries, and from 0.3% to 0.6% in male beneficiaries.

15 uld yield $3.6 million in annual savings for beneficiaries.

16 readmission rates than traditional Medicare beneficiaries.

17 ndard-dose influenza vaccines among Medicare beneficiaries.

18 beneficiaries, and from 0.3% to 1.6% in male beneficiaries.

19 ifying exacerbation events occurred in 1,354 beneficiaries.

20 ending thoracic aortic aneurysms in Medicare beneficiaries.

21 controls from a 5% random sample of Medicare beneficiaries.

22 functioning and economic decision-making in beneficiaries.

23 ted analyses on 881,381 commercially insured beneficiaries.

24 s to increase price competition for Medicare beneficiaries.

25 ablishing a communication strategy vis a vis beneficiaries.

26 infarction (AMI) are calculated for Medicare beneficiaries.

27 d mortality compared with nondually enrolled beneficiaries.

28 rove the value of care delivered to Medicare beneficiaries.

29 re commonly studied as both facilitators and beneficiaries.

30 .06%-8.13%) in 2017 among nondually enrolled beneficiaries.

31 nefit all patients, not just fee-for-service beneficiaries.

32 materials and condensed matter sciences are beneficiaries.

33 presages significant mortality for Medicare beneficiaries.

34 tions were more likely in dementia-diagnosed beneficiaries.

35 We studied 12.7 million vaccinated beneficiaries.

36 Of these beneficiaries, 11 697 900 (16.5%) were dually enrolled i

37 Of 248 345 beneficiaries, 16.4% were patients of high-testing physi

38 alence was 5.28% overall, 7.78% among female beneficiaries, 2.96% among male beneficiaries and increa

39 imental study of 1,981,095 national Medicare beneficiaries (2007-2014) undergoing general, vascular,

40 Working with a 20% random sample of Medicare beneficiaries (2008 to 2015), we identified those with c

41 data from a 20% national sample of Medicare beneficiaries (2008-2014).

42 iod from 162 per 1000 (2004) to 172 per 1000 beneficiaries (2013) (Ptrend <0.001 for both).

43 , black (15.0% vs 7.6%, P < 0.001), Medicaid beneficiaries (22.0% vs 6.4%, P < 0.001), and in the low

44 Among 603,105 Medicare beneficiaries, 32,145 patients (5.3%) were categorized a

45 In a cohort of 18.9 million Medicare beneficiaries (4.2 million deaths) living across the con

46 Among 899 physician practices with 5189880 beneficiaries, 547 practices were categorized as low ris

47 Our sample size included 5073 beneficiaries: 55% were female, 45% were >/=85 years of

48 Medicare beneficiaries 65 years old or older admitted for five me

49 Among 366 103 CR-eligible beneficiaries, 89 327 (24.4%) participated in CR, of who

50 s likely to care for more than 1000 Medicare beneficiaries (9.4% vs 17.8%; difference, -8.3 percentag

51 tes were similar among aligned and unaligned beneficiaries, ACO care was associated with fewer all-ca

52 thin 6 months of an admission (referenced to beneficiaries admitted but without the characteristic) a

53 onal study of rural Medicare Fee-for-Service beneficiaries admitted to US CAHs and non-CAHs for pneum

54 edicaid beneficiaries, with a mean of 606039 beneficiaries affected by plan exits annually.

55 assessed the incidence of AKI among Medicare beneficiaries after PCI from 2004 to 2009 and subsequent

56 Medicare beneficiaries age 65 to 99 who underwent surgery for pan

57 travel time to cancer care site for Medicare beneficiaries age 65 years or older in the southeastern

58 to 47%) probability of receiving IMiDs among beneficiaries age 75 to 84 years and a significantly low

59 We analyzed Medicare beneficiaries aged >=65 years receiving intravenous thro

60 ohort study from 2012 to 2018 among Medicare beneficiaries aged >=65 years was performed.

61 Retrospective cohort study on Medicare beneficiaries aged >=65 years who received an influenza

62 population-based; study population: Medicare beneficiaries aged >=65 years who underwent EK procedure

63 Medicare beneficiaries aged >=65 years who underwent endothelial

64 mber 30, 2016 among Medicare Fee-for-Service beneficiaries aged >=65 years.

65 0% random sample of Medicare fee-for-service beneficiaries aged 65 to 99 years who underwent 1 of 13

66 There were 71 017 608 unique Medicare beneficiaries aged 65 years or older (mean age, 75.6 [SD

67 -sectional study of Medicare fee-for-service beneficiaries aged 65 years or older between January 200

68 ctional analysis of Medicare fee-for-service beneficiaries aged 65 years or older from 1999 to 2014 u

69 : A cross-sectional study involving Medicare beneficiaries aged 65 years or older who underwent 1 of

70 retrospective cohort study included Medicare beneficiaries aged 65 years or older who were treated fo

71 Among Medicare fee-for-service beneficiaries aged 65 years or older, dually enrolled be

72 Medicare beneficiaries aged 66 to 75 years (n = 29932) and older

73 In beneficiaries aged 70 to 74 years, the 8-year risk for C

74 VE) of all influenza vaccines among Medicare beneficiaries ages >65 years to prevent influenza hospit

75 the RVE of influenza vaccines among Medicare beneficiaries ages >=65 years during the 2018-2019 seaso

76 Combining data for fee-for-service beneficiaries and estimates for Medicare Advantage benef

77 26.58%-26.84%) in 2017 among dually enrolled beneficiaries and from 18.1% (95% CI, 18.11%-18.17%) in

78 , 8.05%-8.13%) in 2017 among dually enrolled beneficiaries and from 4.1% (95% CI, 4.08%-4.13%) in 200

79 10.02%-10.20%) in 2017 among dually enrolled beneficiaries and from 8.5% (95% CI, 8.50%-8.56%) in 200

80 among female beneficiaries, 2.96% among male beneficiaries and increased with age from 0.20% for ages

81 U.S. fee-for-service Medicare beneficiaries and Oklahoma ophthalmologist and optometri

82 In this observational cohort study, beneficiaries and their physicians were analyzed using 2

83 to 0.9% overall, from 0.8% to 1.2% in female beneficiaries, and from 0.3% to 0.6% in male beneficiari

84 to 3.0% overall, from 1.4% to 4.5% in female beneficiaries, and from 0.3% to 1.6% in male beneficiari

85 ed by a higher frequency of whites, Medicare beneficiaries, and lower rates of cardiac arrest.

86 ms database (2013-2017), covering 12 million beneficiaries annually.

87 2015) to the performance period (2016) among beneficiaries attributed to AIM ACOs with concurrent cha

88 ontracts to 2014 with concurrent changes for beneficiaries attributed to local non-ACO providers (con

89 orm of delayed surgery and falls in Medicare beneficiaries awaiting cataract surgery.

90 Comparing 196 beneficiaries before and after debt relief, and controll

91 Among 299,583 Medicare beneficiary beneficiaries who underwent a colectomy (n =

92 We studied all Medicare fee-for-service beneficiaries between 1999 and 2013, and we evaluated ra

93 Data from Medicare beneficiaries between 2005 and 2015 (5% random samples)

94 sitive effects, with facilitators increasing beneficiaries by, on average, 81% across all taxa and re

95 Measures were assessed overall, by beneficiary characteristics and geography, and by primar

96 (Medicare, Medicaid, and dual-eligible), and beneficiary characteristics within each insurance group

97 The median annual cost of the drugs per beneficiary covered by the programs was $1157 (interquar

98 include a sepsis code, the setting differed: beneficiaries destined for a sepsis admission were more

99 Although Medicare beneficiaries destined for an inpatient hospital admissi

100 d long-term survival between 16 886 Medicare beneficiaries diagnosed with an acute type A aortic diss

101 US Medicare beneficiaries diagnosed with dementia are less likely to

102 Some 73.4% of beneficiaries diagnosed with dementia saw an eye care pr

103 ing SEER-Medicare data, we identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011.

104 dial infarction hospital discharge, 15.4% of beneficiaries discontinued statins.

105 tified a DED population from 9.7 million MHS beneficiaries (DOD service members, retirees, and depend

106 Beneficiary driving distances and times to his or her YA

107 Medicaid beneficiaries enrolled in exiting plans had access to co

108 Among 1,035,536 Medicare beneficiaries followed for a mean of 5.2 years, 15,531 (

109 rican American, Hispanic, and Asian Medicare beneficiaries for coronary artery bypass grafting, colec

110 dels of the cost of sepsis care for Medicare beneficiaries forecast arise approximately 13% over 2 ye

111 alence of cardiac amyloidosis among Medicare beneficiaries from 2000 to 2012.

112 e cohort of Taiwan National Health Insurance beneficiaries from 2000 to 2013.

113 HODS AND In a national 5% sample of Medicare beneficiaries from 2002 to 2013, we identified a cohort

114 ims data from a 5% random sample of Medicare beneficiaries from 2008 to 2015.

115 -year mortality increased among hospitalized beneficiaries from 23.1% (95% CI, 23.05%-23.20%) in 2004

116 es comparisons of changes for ACO-attributed beneficiaries from before the start of ACO contracts to

117 We identified 12,420 Medicare beneficiaries from the National Cardiovascular Data Regi

118 e of NO, endothelial cells, to the potential beneficiary from the lactate, neurons-prompts new questi

119 ase was related to a decline in SNF days per beneficiary (from 26.2 to 21.3 days in BPCI SNFs and fro

120 The authors identified 90,869 Medicare beneficiaries >/=65 years of age who had prescriptions f

121 of 2 331 939 unique fee-for-service Medicare beneficiaries >/=65-years-old followed for all inpatient

122 Three in 10 Medicare beneficiaries had a preexisting mental illness diagnosis

123 ht to determine whether US minority Medicare beneficiaries had disproportionately low costs compared

124 ries aged 65 years or older, dually enrolled beneficiaries had higher annual all-cause mortality, all

125 Medicare Advantage beneficiaries had higher risk-adjusted 30-day readmissio

126 Beneficiaries had Medicare fee-for-service coverage incl

127 : For the same dollar amount of relief, some beneficiaries had more debt accounts eliminated, while o

128 Being a BFP beneficiary had a positive effect for cure (average effe

129 on: The prevalence of PBC among the Medicare beneficiaries has increased.

130 e also enrolled in Medicaid (dually enrolled beneficiaries) have drawn the attention of policy makers

131 ed claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, at 4446 acu

132 Among fee-for-service Medicare beneficiaries hospitalized for COPD, initiation of pulmo

133 Among Medicare fee-for-service beneficiaries hospitalized for heart failure, acute myoc

134 For rural Medicare beneficiaries hospitalized from 2007 to 2017, CAHs submi

135 ents including, but not limited to, Medicare beneficiaries in 2018.

136 s (2002-2006), including 28 million Medicare beneficiaries in 708 counties.

137 The study included >19 million vaccinated beneficiaries in a community pharmacy setting.

138 1-year mortality rate was 40% among Medicare beneficiaries in GWTG-HF who survived to hospital discha

139 ortality on an additive scale among Medicare beneficiaries in Massachusetts (2000-2012).

140 actices may result in the largest savings to beneficiaries in Michigan.

141 ed to AIM ACOs with concurrent changes among beneficiaries in the comparison group.

142 Beneficiaries in the highest 10% of total standardized i

143 Among the 68374904 unique Medicare beneficiaries in the study, there were 469582 hospitaliz

144 or Medicare & Medicaid Services for Medicare beneficiaries in the United States and is intended to as

145 including an explicit sepsis code for those beneficiaries in those calendar years rose from $17,792,

146 d more than $10 000 in Medicare spending per beneficiary in 2016.

147 Although the median spending per Medicare beneficiary in the year after surgery was higher for sup

148 tality between dually and nondually enrolled beneficiaries increased between 2004 (adjusted odds rati

149 l number of prescriptions among all Medicaid beneficiaries increased, with gains of 89.7% in statins

150 i.e., supply, demand, and flow) for multiple beneficiaries into the decision problem underpinning SCP

151 CDC vulnerability index (SVI) dataset at the beneficiary level of residence.

152 ions (17% CAH) for 2 850 194 unique Medicare beneficiaries (mean [SD] age, 76.3 [11.7] years; 55.5% w

153 total of 6,375 inpatient/outpatient Medicare beneficiaries (mean age 69.8 years, 17% male, 88% white,

154 t arteriovenous access was performed in 1479 beneficiaries (mean age, 63 years +/- 15 [standard devia

155 ere high medical and social risk (mean, 1858 beneficiaries; mean, 269 clinicians).

156 , 102 were high social risk only (mean, 1635 beneficiaries; mean, 284 clinicians), and 122 were high

157 gh social nor high medical risk) (mean, 7909 beneficiaries; mean, 320 clinicians), 128 were high medi

158 128 were high medical risk only (mean, 3675 beneficiaries; mean, 370 clinicians), 102 were high soci

159 e (DOD) Military Health System (MHS) data on beneficiary medical claims from United States DOD milita

160 A total of 4 451 200 beneficiaries met inclusion criteria; 3 805 718 (85.5%)

161 nctioning of eliminating one debt account, a beneficiary must receive debt relief worth ~1 month's ho

162 riatric surgery is increasing among Medicare beneficiaries, no long-term, national studies examining

163 rnments, and the people who are the intended beneficiaries of development programming.

164 en's Health Initiative participants who were beneficiaries of Medicare Parts A&B fee-for-service.

165 longitudinal cohort study, patients who were beneficiaries of Medicare undergoing their first arterio

166 filled prescription rates per 1000 Medicaid beneficiaries of statins, antihypertensives, P2Y12 inhib

167 ncluded in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not.

168 1 and March 11, 2020, were matched to 30,759 beneficiaries of the Regional Health Service (controls)

169 ry and the truism that the authors are prime beneficiaries of the review process.

170 we estimated the propensity score of being a beneficiary of the BFP using a logit model.

171 n quarterly prescriptions (per 1000 Medicaid beneficiaries) of statins (DID estimate [95% CI]: 22.5 [

172 for a random 5% sample of 1 618 059 Medicare beneficiaries older than 66 years.

173 Results were similar among beneficiaries older than 75 years of age.

174 lso more likely to be performed for Medicare beneficiaries (OR=2.12, 95% CI 1.08-4.15) than for priva

175 2004 to 41 121 in 2017 among dually enrolled beneficiaries (P < .001) and from 29 000 in 2004 to 22 6

176 4 to 22 601 in 2017 among nondually enrolled beneficiaries (P < .001); however, the difference betwee

177 Only 1 in 4 CR-eligible Medicare beneficiaries participated in CR and marked disparities

178 l changes in intended management in Medicare beneficiaries participating in the National Oncologic PE

179 Our study included ~1.6 million beneficiaries per year.

180 ion in total Medicare spending of $28.21 per beneficiary per month relative to the comparison group,

181 orresponded to a net reduction of $10.46 per beneficiary per month.

182 tcomes between dually and nondually enrolled beneficiaries persisted during the study period.

183 tering predominantly ranibizumab to Medicare beneficiaries pre-CATT, 221 (69.7%) reduced ranibizumab

184 d beneficiaries were matched to unvaccinated beneficiaries (primary analysis) and to HZV-unvaccinated

185 We estimated linear regression models at the beneficiary-quarter level to evaluate changes in healthc

186 s (change, -$118 [95% CI, -$151 to -$85] per beneficiary-quarter) and improvements in all 4 quality i

187 h spending (change, $5 [CI, -$51 to $62] per beneficiary-quarter) or quality.

188 I, -0.32 to -0.16 hospitalizations] per 1000 beneficiary-quarters) but not in the instrumental variab

189 CI, -0.10 to 0.20 hospitalizations] per 1000 beneficiary-quarters).

190 sed on improving the individual power of the beneficiaries, rather than working on broader systems of

191 tudy, we used data from a cohort of Medicare beneficiaries receiving hemodialysis included in the US

192 an ophthalmologist versus 86.7% and 74.0% of beneficiaries, respectively, without dementia diagnoses.

193 Of >13 million beneficiaries, RVE for cell-cultured vaccines relative t

194 ntified from diagnosis codes documented in a beneficiary's first 3 years of observed Medicare enrollm

195 ied from diagnosis codes on or prior to each beneficiary's first-eye cataract surgery.

196 conventional regression to predict Medicare beneficiary sepsis costs.

197 e separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not expose

198 ohort study of 2016 to 2017 Medicare Current Beneficiary Survey data (n=3614) linked to Medicare fee-

199 acilitators had stronger positive effects on beneficiaries than non-invasive facilitators.

200 The overall proportion of beneficiaries that first received ranibizumab for neovas

201 Among 12 777 214 beneficiaries, the egg-based adjuvanted (RVE, 7.7%; 95%

202 h screening is covered for eligible Medicare beneficiaries, the generalizability of the NLST in the e

203 Among Medicare beneficiaries, the majority of the differences in outcom

204 Among hospitalized beneficiaries, the risk-adjusted 30-day mortality rates

205 search include understudied facilitators and beneficiaries, the stress gradient hypothesis, patterns

206 Compared with unaligned beneficiaries, those cared for by ACOs without cardiolog

207 n rates for elderly Medicare fee-for-service beneficiaries through day-60 post-discharge following a

208 omy among a large group of managed care plan beneficiaries throughout the United States.

209 anel-negative binomial models on a subset of beneficiaries to compare their acute medical service uti

210 After propensity score matching BFP beneficiary to nonbeneficiary families, we used Mantel-H

211 Among hospitalized Medicare beneficiaries treated by a general internist, there were

212 g a 20% national Medicare sample to identify beneficiaries undergoing 1 of 7 common surgical procedur

213 Among Medicare beneficiaries undergoing an elective HP resection, more

214 The number of Medicare beneficiaries undergoing any glaucoma therapeutic proced

215 We analyzed data on elderly Medicare beneficiaries undergoing any of 4 elective inpatient sur

216 Among US Medicare beneficiaries undergoing cataract surgery, those with de

217 s a cross-sectional cohort study of Medicare beneficiaries undergoing colectomy (189229 patients at 1

218 We identified 457,128 beneficiaries undergoing first-eye cataract surgery, 23,

219 Among Medicare beneficiaries undergoing gastric band surgery, device-re

220 ed 30-day mortality among 1,483,074 Medicare beneficiaries undergoing general and orthopedic operatio

221 ces in postoperative outcomes among Medicare beneficiaries undergoing HP procedures.

222 mes or lower episode payments among Medicare beneficiaries undergoing inpatient surgery.

223 lation-based study was conducted of Medicare beneficiaries undergoing laparoscopic or open colectomy

224 ed by a representative sample of US Medicare beneficiaries using self-reported visual function, reinf

225 for 39.6% of total spending for all Medicare beneficiaries versus only 8.4% among low-utilizers.

226 ion and in-hospital mortality among Medicaid beneficiaries versus privately insured individuals hospi

227 A beneficiary was counted in the incidence cohort only dur

228 sample of national fee-for-service Medicare beneficiaries, we calculated episode payments for patien

229 ciaries and estimates for Medicare Advantage beneficiaries, we estimate the total inpatient admission

230 f data from Taiwan National Health Insurance beneficiaries, we found that use of PPIs in patients wit

231 Using a random 20% sample of US Medicare beneficiaries, we framed our study as a series of nonran

232 For each beneficiary, we identified all hospital admissions, outp

233 r we controlled for year of treatment, black beneficiaries were 45% less likely to receive ranibizuma

234 Methods and Results Medicare beneficiaries were counted in the prevalence cohort in e

235 Beneficiaries were followed until December 2017 for MI,

236 HZV-vaccinated beneficiaries were matched to unvaccinated beneficiaries

237 Dementia-diagnosed beneficiaries were more likely to have surgeries coded a

238 ts of the intervention, whereas the ultimate beneficiaries were pregnant women attending ANC.

239 Medicare beneficiaries who are also enrolled in Medicaid (dually

240 Among the subset of beneficiaries who did see ophthalmologists, those with d

241 ishable by accumulated diagnostic codes from beneficiaries who had an index hospital admission withou

242 g vaccinated beneficiaries with unvaccinated beneficiaries who had an outpatient health-care visit du

243 rollment data for a group of fee-for-service beneficiaries who had been attributed to 41 AIM ACOs and

244 In contrast, comparing beneficiaries who had been free of any inpatient admissi

245 covariates and in an analysis that included beneficiaries who had five or more chronic medical condi

246 s (primary analysis) and to HZV-unvaccinated beneficiaries who had received pneumococcal vaccination

247 Among 1,889,032 Medicare beneficiaries who met inclusion criteria 560,744 (n = 29

248 -pocket costs for qualifying Medicare Part D beneficiaries who receive orally administered chemothera

249 as no difference in driving distance between beneficiaries who received a laser capsulotomy from an o

250 Among Medicare beneficiaries who received PTA, stent placement, atherec

251 to 41 AIM ACOs and for a comparable group of beneficiaries who resided in the ACO markets but were se

252 We used national Medicare data to identify beneficiaries who underwent 1 of 19 major surgical proce

253 Among Medicare beneficiaries who underwent a range of surgical procedur

254 Medicare beneficiaries who underwent an elective HP surgery betwe

255 rescribed in 2016 to 88% of 591 733 Medicare beneficiaries who underwent cataract surgery during that

256 Using national data of Medicare beneficiaries who underwent common surgical procedures,

257 Medicare beneficiaries who underwent elective colectomy, coronary

258 med a retrospective cohort study of Medicare beneficiaries who underwent TAVR or SAVR between 2012 an

259 Comparing all beneficiaries who were admitted to a skilled nursing fac

260 We identified Medicare fee-for-service beneficiaries who were CR eligible in 2016, and assessed

261 t included a sepsis code not only identifies beneficiaries who were less resilient to infection but a

262 compared the outcomes among ESRD-HD Medicare beneficiaries who were managed with TAVR, surgical AVR (

263 patient hospital admission was similar among beneficiaries who would be admitted for sepsis versus th

264 aggregate costs of sepsis care for Medicare beneficiaries will continue to increase.

265 eate (1) a cohort of 295 494 fee-for-service beneficiaries with >=1 hospitalization for heart failure

266 mortality rates for Medicare fee-for-service beneficiaries with a sepsis inpatient admission remain h

267 umber of Medicare Part A/B (fee-for-service) beneficiaries with an inpatient hospital admission assoc

268 the likelihood of receiving eye care between beneficiaries with and without dementia.

269 t-of-pocket (OOP) costs incurred by Medicare beneficiaries with cancer and identify which factors and

270 Annual spending for beneficiaries with cardiovascular disease was ~$200 lowe

271 pared with those without dementia diagnoses, beneficiaries with diagnosed dementia had lower likeliho

272 Overall, 8% of 754,777 beneficiaries with ESRD underwent at least one lower ext

273 ed a mortality follow-back study of Medicare beneficiaries with ESRD who died in 2002 through 2014 to

274 In this article, we use a cohort of Medicare beneficiaries with heart failure with reduced ejection f

275 Compared to beneficiaries with high statin adherence, statin intoler

276 We limited the study population to beneficiaries with incident CSC diagnosed by an eye care

277 Among Medicare beneficiaries with MCI or dementia of uncertain etiology

278 changes in clinical management for Medicare beneficiaries with MCI or dementia.

279 Conclusion Medicare beneficiaries with myeloma who do not receive LISs face

280 013), and (3) afterward for 164,188 Medicare beneficiaries with neovascular macular degeneration rece

281 Beneficiaries with no sepsis inpatient hospital admissio

282 propensity-score matched cohorts of Medicare beneficiaries with PAD from 2006 through 2009.

283 Most inpatient admissions for US Medicare beneficiaries with primary ophthalmic diagnoses were for

284 mortality rates for Medicare fee-for-service beneficiaries with pulmonary embolism (PE) between 1999

285 ariate-adjusted hazard ratios (HR) comparing beneficiaries with statin intolerance versus those with

286 In unadjusted analyses, Medicaid beneficiaries with STEMI had lower rates of coronary rev

287 Medicaid beneficiaries with STEMI had lower rates of revasculariz

288 Population consisted of beneficiaries with type 2 diabetes mellitus (T2DM).

289 Among Medicare beneficiaries with type 2 diabetes, implementation of a

290 nonrandomized "trials" comparing vaccinated beneficiaries with unvaccinated beneficiaries who had an

291 We identified Medicare beneficiaries with XFG or POAG and >=5 years of continuo

292 atient total yearly charges and payments per beneficiary with PBC increased from $3,065 and $777 (200

293 atient total yearly charges and payments per beneficiary with PBC increased from $59,765 and $19,406

294 59) minutes for the 23,382 included Medicare beneficiaries, with 24% of patients traveling longer tha

295 hanges in the epidemiology of HF in Medicare beneficiaries, with a decline in incident HF and a decre

296 hese exiting plans enrolled 4848310 Medicaid beneficiaries, with a mean of 606039 beneficiaries affec

297 riptive analysis of Medicare fee-for-service beneficiaries, with at least one home health claim betwe

298 y demographics and comorbidities to Medicare beneficiaries without cancer, who served as controls.

299 less likely to receive cataract surgery than beneficiaries without diagnosed dementia (HR, 0.62; 95%

300 ast year of life compared with 1% of 958,412 beneficiaries without ESRD.

301 r of life compared with a parallel cohort of beneficiaries without ESRD.

302 All-cause hospitalizations per 100 000 beneficiary-years declined from 49 888 in 2004 to 41 121

303 Revascularization rates per 100000 beneficiary-years of fee-for-service enrollment, in-hosp